<DOC>
	<DOCNO>NCT00258336</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some find cancer cell kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Vaccines make person 's cancer cell may help body build effective immune response kill cancer cell . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving rituximab together vaccine therapy GM-CSF may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together vaccine therapy GM-CSF work treat patient indolent B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab , Vaccine Therapy , GM-CSF Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy immunotherapy comprise rituximab , autologous immunoglobulin idiotype-KLH conjugate vaccine ( FavId™ ) , sargramostim ( GM-CSF ) , term response rate ( partial complete ) event-free survival , patient indolent B-cell non-Hodgkin 's lymphoma . - Determine safety regimen patient . - Evaluate development immune response patient treat regimen . OUTLINE : This open-label , multicenter study . - Induction therapy : Patients receive rituximab IV 2-4 hour weekly 4 week . Patients evaluated response month 3 . Patients respond stable disease proceed maintenance therapy . Patients progressive disease remove study . - Maintenance therapy : Patients receive rituximab induction therapy month 7 , 13 , 19 . Patients also receive autologous immunoglobulin idiotype-KLH conjugate vaccine ( FavId™ ) subcutaneously ( SC ) day 1 sargramostim ( GM-CSF ) SC daily day 1-4 month 4-6 , 8-11 , 14 , 16 , 18 , 20 , 22 , 24 . Patients continue response complete 2 year therapy may continue receive FavId™ GM-CSF every 3 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 56 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm indolent Bcell nonHodgkin 's lymphoma 1 follow subtypes : Grade 1 2 follicular lymphoma Tumor must accessible biopsy biopsy material available preparation autologous immunoglobulin idiotypeKLH conjugate vaccine ( FavId™ ) Measurable evaluable disease node biopsy No mantle cell , marginal zone , MALTtype , small lymphocytic , grade 3 follicular ( follicular large cell ) lymphoma No CNS involvement lymphoma PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Not specify Hematopoietic Platelet count &gt; 100,000/mm^3 WBC ≥ 3,000/mm^3 Hepatic AST ALT ≤ 2 time upper limit normal Bilirubin ≤ 2 mg/dL Renal Creatinine ≤ 1.5 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day completion study treatment HIV negative No medical psychiatric disease would preclude study compliance No malignancy ( active treat ) within past 5 year PRIOR CONCURRENT THERAPY : Radiotherapy Prior local radiotherapy allow Other No prior anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
</DOC>